RESEARCH ADVANCE The Plasmodium liver-specific protein 2 (LISP2) is an early marker of liver stage development Devendra Kumar Gupta1,2†, Laurent Dembele2,3†, Annemarie Voorberg-van der Wel4, Guglielmo Roma5, Andy Yip2, Vorada Chuenchob6, Niwat Kangwanrangsan7, Tomoko Ishino8, Ashley M Vaughan6, Stefan H Kappe6, Erika L Flannery6, Jetsumon Sattabongkot9, Sebastian Mikolajczak1,6, Pablo Bifani2,10,11, Clemens HM Kocken4, Thierry Tidiane Diagana1,2* 1Novartis Institute for Tropical Diseases, Emeryville, United States; 2Novartis Institute for Tropical Diseases, Singapore, Singapore; 3Faculty of Pharmacy, Universite´ des Sciences, des Techniques et des Technologies de Bamako (USTTB), MRTC – DEAP, Bamako, Mali; 4Department of Parasitology, Biomedical Primate Research Centre, Rijswijk, Netherlands; 5Novartis Institutes for BioMedical Research, Basel, Switzerland; 6Center for Infectious Disease Research, Seattle, United States; 7Faculty of Science, Mahidol University, Bangkok, Thailand; 8Graduate School of Medicine, Ehime University, Toon, Japan; 9Faculty of Tropical Medicine, Mahidol Vivax Research Center, Bangkok, Thailand; 10Singapore Immunology Network (SIgN), Singapore, Singapore; 11Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore *For correspondence:
[email protected] Abstract Plasmodium vivax hypnozoites persist in the liver, cause malaria relapse and represent a major challenge to malaria elimination. Our previous transcriptomic study provided a novel †These authors contributed equally to this work molecular framework to enhance our understanding of the hypnozoite biology (Voorberg-van der Wel A, et al., 2017). In this dataset, we identified and characterized the Liver-Specific Protein 2 Competing interest: See (LISP2) protein as an early molecular marker of liver stage development. Immunofluorescence page 17 analysis of hepatocytes infected with relapsing malaria parasites, in vitro (P.